Pure SS-31 Research peptide

• Research-grade mitochondrial-targeted peptide
• Investigated in laboratory studies of mitochondrial function and cellular energetics
• Research focus includes cellular stress and mitochondrial biology
• Supplied for research purposes only

REFERENCE RECONSTITUTION INFORMATION

This guide explains how research peptides are commonly reconstituted using bacteriostatic water (BAC water), and shows how dosing volumes correspond to syringe units. Always follow sterile preparation techniques when handling research peptides.

Always follow sterile preparation techniques when handling research peptides.

⚠️ DISCLAIMER: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

General Preparation

⚠️ Important: Allow product vial and BAC water to reach room temperature before reconstituting to reduce condensation uptake

• Allow vial to reach room temperature before preparation
• Draw 3ml bacteriostatic water using a sterile syringe
• Inject slowly down the inside wall of the vial
• Avoid foaming
• Gently swirl until fully dissolved
• Do not shake vigorously
• Label with the reconstitution date
• Refrigerate at 2°C–8°C
• Protect from direct light exposure

Reference Handling Information

Reference information for laboratory handling of SS-31.

• Protocol Overview
• Goal: Support Mitochondrial Function & Cellular Energy Research
• Route: Subcutaneous
• Schedule: 5 days on 2 days off
• Dose Range: 5mg–20mg, 5 days on 2 days off
• Reconstitution: 3ml BAC Water
• Final Concentration: 16.67mg/ml
• Storage: Refrigerated After Reconstitution

SS-31 (10mg) - RECONSTITUTION TABLES

Standard Dosing Protocol

PhaseDoseUnitsVolumeWeeks 1–25mg30 Units0.30mlWeeks 3–810mg60 Units0.60mlThese parameters are drawn from published research for reference purposes only. They do not constitute medical or dosing advice. For laboratory research only.

Advanced Dosing Protocol

PhaseDoseUnitsVolumeWeeks 1–25mg30 Units0.30mlWeeks 3–410mg60 Units0.60mlWeeks 5–815mg90 Units0.90mlWeeks 9–12 (Optional)20mg120 Units1.20mlThese parameters are drawn from published research for reference purposes only. They do not constitute medical or dosing advice. For laboratory research only.

Experimental Study Period

STUDY PERIOD8–12 weeksClinical research commonly ranges from 4–12 weeks Consistent daily administration is commonly utilised Rotate injection sites regularly. These tables show common research dosages. Always use an insulin syringe marked with units for accurate measurement. Contact our research support team for additional guidance.

What is SS-31?

SS-31, also known as Elamipretide (MTP-131), is a synthetic mitochondria-targeted tetrapeptide being studied for its effects on mitochondrial structure and function. Research has focused particularly on its interaction with cardiolipin in the inner mitochondrial membrane. 

How does SS-31 work?

SS-31 is designed to target mitochondria and interact with cardiolipin, a phospholipid found in the inner mitochondrial membrane. Research suggests this interaction may influence mitochondrial membrane organization, bioenergetics and oxidative processes. 

What is SS-31 used for in research?

SS-31 has been investigated in research involving mitochondrial dysfunction, mitochondrial myopathy, cardiovascular function, muscle function and age-related conditions. Human clinical trials have examined elamipretide in several mitochondrial disorders, while substantial additional evidence comes from preclinical research. 

Is SS-31 a mitochondrial peptide?

Yes. SS-31 is classified as a mitochondria-targeted peptide. Its ability to selectively interact with mitochondrial membranes is a major focus of ongoing scientific research. 

What is the difference between SS-31 and Elamipretide?

There is generally no difference in the compound itself. SS-31, Elamipretide and MTP-131 are names used to refer to the same mitochondria-targeted peptide in scientific and clinical literature. 

Has SS-31 been studied in humans?

Yes. Elamipretide has been evaluated in human clinical trials, including studies investigating primary mitochondrial myopathy and other mitochondrial disorders. Results have varied by study and indication, so SS-31 remains an area of ongoing research. 

Is SS-31 approved for general medical use?

SS-31/Elamipretide has been investigated as an experimental therapeutic and is not something that should be represented as an established treatment for general health or disease based solely on research findings. Clinical development and evaluation have continued across several indications. 

Why is SS-31 of interest in mitochondrial research?

Mitochondria play a central role in cellular energy production. SS-31 has attracted research interest because it specifically targets the mitochondrial inner membrane and may influence cardiolipin organization, mitochondrial bioenergetics and oxidative stress pathways. 

Is SS-31 suitable for research purposes?

SS-31 is commonly discussed within laboratory and scientific research relating to mitochondrial biology. Research materials should be handled and used according to applicable laboratory, regulatory and safety requirements.

SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide investigated for its interaction with cardiolipin in the inner mitochondrial membrane. Research has focused on mitochondrial structure and bioenergetics, oxidative stress, ATP-related processes and cellular responses to mitochondrial dysfunction. Elamipretide has also been studied in human clinical trials, but this product is presented strictly for laboratory research. For laboratory research use only.